The protein therapeutics market totaled $63 billion in 2007 ($39 billion in the U.S. alone) and is expected to reach $87 billion by 2010, according to a report by Kalorama Information—“Protein ...

Overcoming common challenges with today’s biologics, such as developing devices for high-concentration subcutaneous ...

This new Aramchol formulation was co-developed by Galmed and Barcode Nanotech, based on Barcode Nanotech's unique and proprietary platform which enables simultaneous screening of hundreds of different ...

A problem for biopharmaceutical companies comes as degraded proteins lead to ineffective and possibly dangerous medicines for their clients. Drug companies work on formulation development to protect ...

Detailed price information for Galmed Pharmaceutica (GLMD-Q) from The Globe and Mail including charting and trades.

WOBURN, Mass.--(BUSINESS WIRE)--ReForm Biologics, a pharmaceutical technology company developing innovative biologic formulations to improve drug delivery and manufacturing, expanded its patent ...

Formulation of biopharmaceuticals poses numerous challenges related to the chemical and physical properties of drugs, and the fact that nearly all such products are injected. Formulation development ...

Stability is one of the main quality characteristics in formulation studies of prospective therapeutic biomolecules. Researchers depend on high-throughput screening techniques to reduce the funds, ...

The global drug formulation market is set for remarkable growth, with total sales projected to increase from USD 1.7 trillion in 2025 to a staggering USD 2.8 trillion by 2035. The market is expected ...

Understand the challenges of liquid injectables and discover strategies to prevent stability issues and regulatory delays.